Literature DB >> 7732900

Mechanism of the prostaglandin-induced reduction of intraocular pressure in humans.

C B Camras1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7732900

Source DB:  PubMed          Journal:  Adv Prostaglandin Thromboxane Leukot Res        ISSN： 0732-8141


× No keyword cloud information.
  7 in total

1.  Changes in ocular surface caused by antiglaucomatous eyedrops: prospective, randomised study for the comparison of 0.5% timolol v 0. 12% unoprostone.

Authors:  J Shimazaki; K Hanada; Y Yagi; J Yamagami; M Ishioka; S Shimmura; K Tsubota
Journal:  Br J Ophthalmol       Date:  2000-11       Impact factor: 4.638

2.  Effect of inhibition of cyclooxygenase on pre- and postjunctional actions of peroxides in the iris-ciliary body.

Authors:  J Graham; S O Awe; A M LeDay; J C Rice; G Ramos; L C Harris; C A Opere; S E Ohia
Journal:  Neurochem Res       Date:  2000-04       Impact factor: 3.996

Review 3.  Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension.

Authors:  S S Patel; C M Spencer
Journal:  Drugs Aging       Date:  1996-11       Impact factor: 3.923

4.  Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension.

Authors:  W Y Zhang; A L Po; H S Dua; A Azuara-Blanco
Journal:  Br J Ophthalmol       Date:  2001-08       Impact factor: 4.638

Review 5.  Travoprost.

Authors:  John Waugh; Blair Jarvis
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

6.  Efficacy and tolerability of a large scale change in regimen from latanoprost to travoprost in glaucoma patients at the Manhattan Veterans Administration Hospital.

Authors:  Edmund P Farris
Journal:  Clin Ophthalmol       Date:  2008-06

7.  Late-day intraocular pressure-lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial.

Authors:  Harvey B DuBiner; Douglas A Hubatsch
Journal:  BMC Ophthalmol       Date:  2014-11-28       Impact factor: 2.209
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.